Join us in our mission to revolutionise immunodiagnostics and to empower better management of complex diseases through creating more insights from a single test

Our strategic vision

Pictor is transforming how diseases are screened, tracked and managed to enable better outcomes in human and animal health

An innovative & unique approach

Pictor’s novel multiplex platform improves human and animal health diagnostics. Our transformative technology has the potential to be a game changer in the fight against infectious diseases in these market segments.

Raising the stakes

The Company’s transition from being solely focused on the low-cost human health diagnostic market of India, to both the high value human health market in the US and livestock diagnostic markets within New Zealand and internationally has continued.

Pictor will enter these new markets in 2022 – 2023 with highly differentiated products:

  • The PictArray SARS-CoV-2 ELISA uniquely detects SP and NP antibodies thus enabling positive differentiation between those who have antibodies as a result of vaccination and those who have been infected with the virus and have suffered from COVID-19.
  • Pictor’s Mycoplasma bovis (M. bovis) multiplex diagnostic with up to five [5] antigens will help accelerate and assist the eradication of this disease from New Zealand.
  • The Pictor Johne’s disease/MAP (Mycobacterium avium subspecies paratuberculosis) diagnostic enables earlier detection and management of this productivity impacting disease that is endemic in New Zealand and other livestock-focused markets. 
You can view introductory company documents in our – CRIISP deal room – or request an investor deck via the form below.

Request our introductory investor deck.

Everything you and your advisors need to know about becoming a part of Pictor's success.

    Trusted Brand

    Pictor has been collaborating with industry leaders from around the globe.

    Labtests Integrity Sciences Mobility Health SVS Laboratories Awanui Group
    Back to top